{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T21:29:17Z","timestamp":1757626157080,"version":"3.44.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Institute on Drug Abuse of the National Institutes","award":["R25DA050985","R25DA050985","R25DA050985","R25DA050985","R25DA050985"],"award-info":[{"award-number":["R25DA050985","R25DA050985","R25DA050985","R25DA050985","R25DA050985"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Amphetamine-type stimulant use and overdoses have increased sharply across the US in recent years, largely driven by methamphetamine. Increased access to treatments for amphetamine-type stimulant use disorder (AT-StUD), including in primary care settings, is needed to mitigate these problems, yet effective behavioral treatments are often inaccessible and there are no FDA-approved medications for AT-StUD. In the current study, we characterize how often patients with clinically documented AT-StUD in predominantly rural-serving Pacific Northwest primary care clinics received medications that have been conditionally recommended in practice guidelines for treatment of AT-StUD.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Electronic health record data from 23 primary care clinics in the Pacific Northwest US were obtained through the Data QUEST network. Adult patients with clinically documented \u201cother stimulant abuse\u201d or \u201cother stimulant dependence\u201d diagnoses typically reflecting AT-StUD between 01\/2017 and 12\/2021 were included. Prescription records were used to identify orders for bupropion, mirtazapine, topiramate, naltrexone-bupropion combination, methylphenidate, dextroamphetamine, and modafinil. Statistical analyses quantified the percentage of patients with medication orders placed within one year after any documented AT-StUD diagnosis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Patients (N\u2009=\u2009963) were predominantly female (53.3%), White (81.7%), and non-Hispanic (70.5%). In total, 14.3% of patients received orders for a non-stimulant medication conditionally recommended in practice guidelines; 2.7% received orders for a stimulant medication. Consistent with clinical guidelines, medications were more often prescribed when patients had documented co-occurring disorders for which the medications could also be effective.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>In this sample of rural-serving primary care clinics, approximately 1 in 7 primary care patients with AT-StUD received orders for medications with preliminary evidence of effectiveness. Efforts are needed to increase access to AT-StUD treatments within primary care. These efforts could include training health professionals to consider judicious use of pharmacotherapy consistent with clinical guidelines, increasing capacity for behavioral health services including contingency management, and continuing research on pharmacologic agents.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13722-025-00593-8","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T06:51:49Z","timestamp":1755067909000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prescribed medications for patients with amphetamine-type stimulant use disorder seen in rural-serving Pacific Northwest primary care clinics"],"prefix":"10.1186","volume":"20","author":[{"given":"Megan J.","family":"Yerton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Connor J.","family":"McCabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew D.","family":"Iles-Shih","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith I.","family":"Tsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin A.","family":"Hallgren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,13]]},"reference":[{"issue":"12","key":"593_CR1","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1001\/jamapsychiatry.2021.2588","volume":"78","author":"B Han","year":"2021","unstructured":"Han B, Compton WM, Jones CM, Einstein EB, Volkow ND. Methamphetamine use, methamphetamine use disorder, and associated overdose deaths among US Adults. JAMA Psychiat. 2021;78(12):1329.","journal-title":"JAMA Psychiat"},{"issue":"12","key":"593_CR2","doi-asserted-by":"publisher","first-page":"317","DOI":"10.15585\/mmwr.mm6912a1","volume":"69","author":"CM Jones","year":"2020","unstructured":"Jones CM, Compton WM, Mustaquim D. Patterns and characteristics of methamphetamine use among Adults \u2014 United States, 2015\u20132018. MMWR Morb Mortal Wkly Rep. 2020;69(12):317\u201323.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"593_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108243","volume":"216","author":"VM McMahan","year":"2020","unstructured":"McMahan VM, Kingston S, Newman A, Stekler JD, Glick SN, Banta-Green CJ. Interest in reducing methamphetamine and opioid use among syringe services program participants in Washington State. Drug Alcohol Depend. 2020;216: 108243.","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"593_CR4","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s40263-020-00711-x","volume":"34","author":"KJ Siefried","year":"2020","unstructured":"Siefried KJ, Acheson LS, Lintzeris N, Ezard N. Pharmacological treatment of methamphetamine\/amphetamine dependence: a systematic review. CNS Drugs. 2020;34(4):337\u201365.","journal-title":"CNS Drugs"},{"issue":"9","key":"593_CR5","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1001\/jamapsychiatry.2020.0246","volume":"77","author":"MP Paulus","year":"2020","unstructured":"Paulus MP, Stewart JL. Neurobiology, clinical presentation, and treatment of methamphetamine use disorder: a review. JAMA Psychiat. 2020;77(9):959.","journal-title":"JAMA Psychiat"},{"issue":"5","key":"593_CR6","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1080\/13543784.2017.1313229","volume":"26","author":"KC Morley","year":"2017","unstructured":"Morley KC, Cornish JL, Faingold A, Wood K, Haber PS. Pharmacotherapeutic agents in the treatment of methamphetamine dependence. Expert Opin Investig Drugs. 2017;26(5):563\u201378.","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"593_CR7","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1097\/ADM.0000000000001035","volume":"17","author":"J Dunn","year":"2023","unstructured":"Dunn J, Yuan M, Ram\u00edrez F, Chokron Garneau H, Brown-Johnson C, Breland H, et al. Addressing methamphetamine use in primary care: provider perspectives. J Addict Med. 2023;17(1):60\u20136.","journal-title":"J Addict Med"},{"issue":"1","key":"593_CR8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/ADM.0000000000001235","volume":"18","author":"Clinical Guideline Committe (CGC) Members, ASAM Team, AAAP Team, IRETA Team","year":"2024","unstructured":"Clinical Guideline Committe (CGC) Members, ASAM Team, AAAP Team, IRETA Team. The ASAM\/AAAP clinical practice guideline on the management of stimulant use disorder. J Addict Med. 2024;18(1):1\u2013223.","journal-title":"J Addict Med"},{"issue":"6","key":"593_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0234809","volume":"15","author":"C Ronsley","year":"2020","unstructured":"Ronsley C, Nolan S, Knight R, Hayashi K, Klimas J, Walley A, et al. Treatment of stimulant use disorder: a systematic review of reviews. PLoS ONE. 2020;15(6): e0234809.","journal-title":"PLoS ONE"},{"key":"593_CR10","first-page":"10","volume":"8","author":"LW Suen","year":"2024","unstructured":"Suen LW, Coffin PO, Boulton KE, Carr DH, Davis CS. Prescribing psychostimulants for the treatment of stimulant use disorder: navigating the federal legal landscape. J Add Med. 2024;8:10\u201397.","journal-title":"J Add Med"},{"issue":"9","key":"593_CR11","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1001\/archinte.166.9.1021","volume":"166","author":"DC Radley","year":"2006","unstructured":"Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med. 2006;166(9):1021.","journal-title":"Arch Intern Med"},{"issue":"7","key":"593_CR12","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1111\/acer.15118","volume":"47","author":"HR Kranzler","year":"2023","unstructured":"Kranzler HR, Hartwell EE. Medications for treating alcohol use disorder: a narrative review. Alcohol, Clin Exp Res. 2023;47(7):1224\u201337.","journal-title":"Alcohol, Clin Exp Res"},{"issue":"2","key":"593_CR13","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1080\/00952990.2023.2175322","volume":"49","author":"KA Hallgren","year":"2023","unstructured":"Hallgren KA, Galloway GP, Witkiewitz K, Linde P, Nix B, Mendelson JE. Treatment retention and reductions in blood alcohol concentration (BAC) during the first 90 days of a telehealth program for alcohol use disorder. Am J Drug Alcohol Abuse. 2023;49(2):249\u201359.","journal-title":"Am J Drug Alcohol Abuse"},{"key":"593_CR14","unstructured":"Matson TE, Oliver M, Steel T, Bradley KA, Hallgren KA. Receipt of AUD medications among primary care patients with an AUD diagnosis in an integrated healthcare system. Poster presented at; 2023 Oct; Addiction Health Services Research Conference; New York, NY."},{"key":"593_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108369","volume":"127","author":"RD Shearer","year":"2021","unstructured":"Shearer RD, Shippee ND, Winkelman TNA. Characterizing trends in methamphetamine-related health care use when there is no ICD code for \u201cmethamphetamine use disorder.\u201d J Subst Abuse Treat. 2021;127: 108369.","journal-title":"J Subst Abuse Treat"},{"issue":"2","key":"593_CR16","doi-asserted-by":"publisher","first-page":"4","DOI":"10.13063\/2327-9214.1206","volume":"4","author":"AM Cole","year":"2016","unstructured":"Cole AM, Stephens KA, Keppel GA, Estiri H, Baldwin LM. Extracting electronic health record data in a practice-based research network: lessons learned from collaborations with translational researchers. eGEMs. 2016;4(2):4.","journal-title":"eGEMs."},{"key":"593_CR17","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ijmedinf.2016.05.008","volume":"93","author":"KA Stephens","year":"2016","unstructured":"Stephens KA, Anderson N, Lin CP, Estiri H. Implementing partnership-driven clinical federated electronic health record data sharing networks. Int J Med Informatics. 2016;93:26\u201333.","journal-title":"Int J Med Informatics"},{"key":"593_CR18","volume-title":"Nonparametric statistics for the behavioral sciences","author":"S Siegel","year":"1988","unstructured":"Siegel S, Castellan NJ Jr. Nonparametric statistics for the behavioral sciences. 2nd ed. New York, NY, England: Mcgraw-Hill Book Company; 1988.","edition":"2"},{"issue":"6","key":"593_CR19","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1111\/j.1365-2125.2010.03639.x","volume":"69","author":"L Karila","year":"2010","unstructured":"Karila L, Weinstein A, Aubin H, Benyamina A, Reynaud M, Batki SL. Pharmacological approaches to methamphetamine dependence: a focused review. Brit J Clinical Pharma. 2010;69(6):578\u201392.","journal-title":"Brit J Clinical Pharma"},{"issue":"1","key":"593_CR20","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13722-021-00267-1","volume":"16","author":"M Yen Li","year":"2021","unstructured":"Yen Li M, Alba GA, Mitton J, Bearnot B. Care-engaged individuals with polysubstance use in Northeastern US are undertreated for methamphetamine use disorder: a retrospective cohort study. Addict Sci Clin Pract. 2021;16(1):57.","journal-title":"Addict Sci Clin Pract"},{"key":"593_CR21","doi-asserted-by":"publisher","DOI":"10.1101\/2022.05.23.22275471","author":"SD Lopera","year":"2022","unstructured":"Lopera SD, O\u2019Kane VM, Goldhirsh JL, Piper BJ. Regional disparities in prescription methamphetamine and amphetamine distribution across the United States. J Attent Dis. 2022. https:\/\/doi.org\/10.1101\/2022.05.23.22275471.","journal-title":"J Attent Dis"},{"issue":"1","key":"593_CR22","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1001\/jamapsychiatry.2022.3788","volume":"80","author":"M Hartikainen","year":"2023","unstructured":"Hartikainen M, Taipale H, Tanskanen A, Mittendorfer-Rutz E, L\u00e4hteenvuo M, Tiihonen J. Association of pharmacological treatments and hospitalization and death in individuals with amphetamine use disorders in a swedish nationwide cohort of 13 965 patients. JAMA Psychiat. 2023;80(1):31.","journal-title":"JAMA Psychiat"},{"issue":"5","key":"593_CR23","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.4585","volume":"2","author":"M Tibuakuu","year":"2019","unstructured":"Tibuakuu M, Okunrintemi V, Jirru E, EchouffoTcheugui JB, Orimoloye OA, Mehta PK, et al. National trends in cessation counseling, prescription medication use, and associated costs among US adult cigarette smokers. JAMA Netw Open. 2019;2(5): e194585.","journal-title":"JAMA Netw Open"},{"issue":"16","key":"593_CR24","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1001\/jama.2022.4790","volume":"327","author":"B Han","year":"2022","unstructured":"Han B, Volkow ND, Blanco C, Tipperman D, Einstein EB, Compton WM. Trends in prevalence of cigarette smoking among us adults with major depression or substance use disorders, 2006\u20132019. JAMA. 2022;327(16):1566.","journal-title":"JAMA"},{"issue":"1","key":"593_CR25","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/jrh.12488","volume":"38","author":"MM Ali","year":"2022","unstructured":"Ali MM, Nye E, West K. Substance use disorder treatment, perceived need for treatment, and barriers to treatment among parenting women with substance use disorder in us rural counties. J Rural Health. 2022;38(1):70\u20136.","journal-title":"J Rural Health"},{"issue":"7","key":"593_CR26","doi-asserted-by":"publisher","DOI":"10.2196\/47516","volume":"6","author":"KA Hallgren","year":"2023","unstructured":"Hallgren KA, Duncan MH, Iles-Shih MD, Cohn EB, McCabe CJ, Chang YM, et al. feasibility, engagement, and usability of a remote, smartphone-based contingency management program as a treatment add-on for patients who use methamphetamine: single-arm pilot study. JMIR Form Res. 2023;6(7): e47516.","journal-title":"JMIR Form Res"},{"issue":"1","key":"593_CR27","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s11414-012-9299-6","volume":"40","author":"S Benavides-Vaello","year":"2013","unstructured":"Benavides-Vaello S, Strode A, Sheeran BC. Using technology in the delivery of mental health and substance abuse treatment in rural communities: a review. J Behav Health Serv Res. 2013;40(1):111\u201320.","journal-title":"J Behav Health Serv Res"},{"issue":"s1","key":"593_CR28","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/j.1748-0361.2007.00128.x","volume":"23","author":"TF Borders","year":"2007","unstructured":"Borders TF, Booth BM. Research on rural residence and access to drug abuse services: where are we and where do we go? J Rural Health. 2007;23(s1):79\u201383.","journal-title":"J Rural Health"},{"issue":"5","key":"593_CR29","doi-asserted-by":"publisher","first-page":"449","DOI":"10.3109\/00952990.2015.1059842","volume":"41","author":"MB Edmond","year":"2015","unstructured":"Edmond MB, Aletraris L, Roman PM. Rural substance use treatment centers in the United States: an assessment of treatment quality by location. Am J Drug Alcohol Abuse. 2015;41(5):449\u201357.","journal-title":"Am J Drug Alcohol Abuse"}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-025-00593-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-025-00593-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-025-00593-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T21:11:05Z","timestamp":1757452265000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpjournal.biomedcentral.com\/articles\/10.1186\/s13722-025-00593-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,13]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["593"],"URL":"https:\/\/doi.org\/10.1186\/s13722-025-00593-8","relation":{},"ISSN":["1940-0640"],"issn-type":[{"type":"electronic","value":"1940-0640"}],"subject":[],"published":{"date-parts":[[2025,8,13]]},"assertion":[{"value":"5 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The use of de-identified electronic health records data was considered non-human subjects research by the University of Washington Institutional Review Board (STUDY00015519).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"67"}}